UNSPSC 51284040: Rolitetracycline nitrate

This classification denotes a tetracycline antibiotic with the molecular structure 2C27H33N3O8.2HNO3.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, TG72BS085Y chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-n-(1-pyrrolidinylmethyl)-, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, mononitrate (salt), sesquihydrate, but more commonly known as rolitetracycline nitrate, which bears US NIH Compound Identifier 5282178.

UNSPSC 51284040 Rolitetracycline nitrate is a Commodity code that nominally identifies a specific tetracycline antibiotic; however, recent state and local opportunities tagged under this code show minimal alignment with the code's abstract scope and instead reflect broader pharmaceutical procurement activity spanning naloxone, first-aid supplies, generic multi-source drugs, and direct-to-manufacturer pharmacy programs. State and local governments soliciting under or near this code are purchasing emergency medical supplies, pharmaceuticals through cooperative purchasing vehicles, and exploring alternative pharmacy benefit structures. Issuing bodies include county health departments (Seminole County, Florida), municipal fire departments (Tampa), and state health and human services agencies (Texas HHS Commission), as well as multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both single-jurisdiction procurement and statewide or multistate cooperative contracting models.

Recent activity concentrates in Florida, Texas, and Minnesota. Representative opportunities include Seminole County's IFB 60459723LAS (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, the City of Tampa's IFB 26P00145 (due March 13, 2026) for 169 line items of medical and first-aid supplies totaling an estimated $700,000 with a 5% small local business enterprise discount, and MMCAP's RFP S1070000015802 (due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The Texas HHS Commission issued an RFI (HHS0017013, April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements. This code's recent activity does not align cleanly with rolitetracycline nitrate procurement; the code appears to be a misfiled or legacy tag for broader pharmaceutical and medical supply categories.